Opthea Limited (AU:OPT) has released an update.
Opthea Limited has reported significant progress in its Phase 3 trials for sozinibercept, a promising therapy for retinal diseases including wet AMD, with both COAST and ShORe trials advancing towards completion. The company’s lead drug candidate aims to enhance vision for patients when combined with standard anti-VEGF-A treatments, potentially becoming the first novel wet AMD therapy in over 15 years. With robust enrolment and positive Phase 2b results, Opthea is bolstering its team and targeting mid-2025 for topline data from these pivotal trials.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.
